哈药股份(600664.SH)：所属企业获得化学原料药上市申请批准通知

Core Viewpoint - Harbin Pharmaceutical Group Co., Ltd. (哈药股份) announced that its subsidiary, Sanjing Ming Shui Pharmaceutical Co., Ltd. (三精明水), received the approval notice for the calcium lactate chemical raw material drug from the National Medical Products Administration, indicating compliance with national drug review technical standards [1] Company Summary - Harbin Pharmaceutical Group's subsidiary, Sanjing Ming Shui, has been granted a marketing approval for calcium lactate, which is primarily used as a calcium supplement in pharmaceutical formulations [1]